SEATTLE, Oct. 26, 2017 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market (By product type: CAR-T cell, bispecific antibodies, and antibody drug conjugates; By indication: acute lymphoblastic leukemia, and multiple myeloma) is expected to grow with increasing need for targeted therapy for multiple myeloma.
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/bcma-targeted-therapies-market-190
Key Trends and Analysis of the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market:
Increasing recurrence of multiple myeloma has been a major obstacle. According to the National Cancer Institute, in 2016, around 75,000 patients globally were recorded to be suffering from relapsed or refractory multiple myeloma, with a relative survival rate of 5 years. B-cell maturation antigen (BCMA) has emerged as a very selective antigen to be targeted for the treatment of multiple myeloma. It possess co-immunoprecipitation property with a master transcription factor (IRF-4) that are mediated for myeloma cell survival. This suggests the potential effect of BCMA in oncogenesis, making it a choice of therapy for multiple myeloma treatment.
Request Sample Copy of the Business Report
Market players are actively involved in the development of immunotherapies targeting BCMA for the treatment of multiple myeloma. These therapies include chimeric antigen receptor T cells, antibody-drug conjugate, and bispecific antibodies. Furthermore, patients undergoing existing drug therapies are prone to the risk of relapse. The robust pipeline therapies for treatment of multiple myeloma is expected to boost growth of the B-cell maturation Antigen (BCMA) targeted therapies market. B-cell maturation antigen targeted therapy, which primarily addresses this concern, is expected to gain rapid traction.
| Company | Therapy | Phase of Research |
| GlaxoSmithKline plc. | Beta cell maturation antigen antibody drug conjugate | Phase 1 |
| bluebird bio, Inc. and Celgene Corporation | Anti-BCMA CAR-T cell therapy | Phase 1 |
| Kite Pharma, Inc. | Anti- BCMA CAR-T cell therapy | Preclinical |
| Nanjing Legend Biotech Co. | CAR-T cell | Phase 1/2 |
| Novartis AG, University of Pennsylvania | CAR-T cell Therapy | Phase 1 |
| Juno Therapeutics, Inc. | CAR-T cell | Phase 1 |
| Boehringer Ingelheim and Amgen | Bispecific Antibody | Phase 1 |
| Affimed | Bispecific Antibody | Preclinical Trials |
| Autolus Limited | CAR-T cell | Phase 1/2 |
Key Market Takeaways:
- According to the American Society of Clinical Oncology (ASCO), in 2016, multiple myeloma was the second most common blood cancer, after non-Hodgkin lymphoma, accounting for 1% of all kinds of malignancies globally, with 70 years being the median age of diagnosis
- As there is no treatment option available for patients with recurrent cancer, development of therapy to treat relapsed and/or refractory multiple myeloma is expected to provide market players with lucrative opportunities
- Some of the major players involved in the development of B-cell maturation antigen (BCMA) targeted therapies market are Celgene Corporation, GlaxoSmithKline plc, Novartis AG, Juno Therapeutics, Gilead Sciences. Inc., Amgen Inc., Affimed N.V, Poseida Therapeutics, Inc., and Autolus Ltd
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com